Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets

According to IMS Health sales data for the 12 month period ending July 2015, the Vfend® market1 achieved annual sales of approximately $91.4 million*.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Voriconazole Tablets, 50 mg and 200 mg, the therapeutic equivalent of Vfend® Tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).   

According to IMS Health sales data for the 12 month period ending July 2015, the Vfend® market1 achieved annual sales of approximately $91.4 million*.  

Glenmark’s current portfolio consists of 102 products authorized for distribution in the U.S. marketplace and 63 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.